Hospital
Rush Medical Foundation
Rush Medical Foundation was paid $29.41M by Medicaid between Jan 2018 and Dec 2024, across 363 billing codes. Its largest line is 99284, emergency room visit (serious) — 14% of everything it billed.
33Billing provider infoRUSH MEDICAL FOUNDATION
MERIDIAN, MS 39301
MERIDIAN, MS 39301
33aNPI1770543399assigned 03/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$29.41M
24GClaims930,209
24DCodes billed363
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#18 of 77
Median peer was paid$8.23M
This provider vs. median3.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KENNEDY, DON controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 161,869 | $4.25M | |
| 2019 | 129,144 | $3.76M | |
| 2020 | 91,716 | $2.74M | |
| 2021 | 117,322 | $3.39M | |
| 2022 | 147,941 | $4.34M | |
| 2023 | 151,932 | $5.71M | |
| 2024incomplete | 130,285 | $5.22M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 23,021 | 18,870 | $4.00M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.1% | 19,930 | 16,901 | $2.67M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.2% | 11,544 | 9,209 | $2.11M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.5% | 27,176 | 21,358 | $1.03M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.1% | 30,648 | 7,280 | $923K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 9,456 | 7,556 | $747K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 8,238 | 7,129 | $698K |
| G0378 | Hospital observation service, per hour | 2.4% | 4,458 | 3,177 | $691K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.2% | 14,702 | 11,931 | $658K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.1% | 514 | 446 | $627K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.1% | 12,859 | 9,847 | $623K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 17,795 | 12,721 | $569K |
351 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.8% | 26,736 | $530K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 6,263 | $490K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.7% | 9,499 | $489K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 2,318 | $454K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 3,375 | $437K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.2% | 107 | $354K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 20,357 | $340K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.1% | 5,509 | $331K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 9,500 | $320K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 8,275 | $317K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 11,790 | $314K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 2,181 | $310K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,880 | $280K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,077 | $273K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,402 | $262K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,134 | $240K |
| 88342 | <1% | 3,452 | $230K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,495 | $209K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,220 | $205K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 655 | $203K |
| 87428 | <1% | 4,415 | $201K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 40,005 | $181K |
| 86900 | <1% | 4,173 | $179K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 2,503 | $178K |
| 20610 | <1% | 1,638 | $171K | |
| 76801 | <1% | 2,585 | $170K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,499 | $167K |
| 97161 | <1% | 4,847 | $166K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,873 | $160K |
| 80053 | Comprehensive metabolic panel | <1% | 24,213 | $155K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,265 | $153K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,231 | $148K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 569 | $146K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,024 | $136K |
| 59025 | Fetal non-stress test | <1% | 1,226 | $127K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,842 | $122K |
| 92523 | <1% | 761 | $116K | |
| 73610 | <1% | 2,821 | $112K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,919 | $110K |
| 93970 | <1% | 1,774 | $109K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,396 | $106K |
| 73560 | <1% | 3,717 | $106K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 5,373 | $104K |
| 73110 | <1% | 2,506 | $102K | |
| 74022 | <1% | 2,145 | $101K | |
| 64493 | <1% | 273 | $101K | |
| 73030 | <1% | 3,307 | $92K | |
| 73130 | <1% | 2,236 | $88K | |
| 73630 | <1% | 2,353 | $88K | |
| 74018 | <1% | 2,820 | $88K | |
| 72100 | <1% | 1,993 | $86K | |
| 86850 | <1% | 4,149 | $85K | |
| 93458 | <1% | 100 | $81K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,253 | $75K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,273 | $75K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 14,259 | $74K |
| 88142 | <1% | 4,871 | $73K | |
| 88304 | <1% | 2,159 | $69K | |
| 73562 | <1% | 2,138 | $69K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,073 | $68K |
| 83880 | <1% | 4,378 | $67K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,366 | $67K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,415 | $65K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,002 | $65K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,271 | $64K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,270 | $64K |
| 84484 | <1% | 11,711 | $64K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,759 | $60K |
| 86901 | <1% | 4,178 | $60K | |
| 72110 | <1% | 1,494 | $59K | |
| 93017 | <1% | 1,123 | $59K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,924 | $54K |
| 74019 | <1% | 906 | $49K | |
| 73502 | <1% | 2,169 | $49K | |
| 93971 | <1% | 1,455 | $47K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,093 | $46K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,042 | $43K |
| 82553 | <1% | 5,134 | $42K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 722 | $39K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 89 | $38K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 504 | $38K |
| 43450 | <1% | 402 | $37K | |
| 80305 | <1% | 6,336 | $37K | |
| 81025 | <1% | 6,455 | $37K | |
| 97162 | <1% | 952 | $36K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,055 | $35K |
| 80061 | Lipid panel | <1% | 2,959 | $35K |
| 76641 | <1% | 774 | $34K | |
| 82962 | <1% | 17,736 | $34K | |
| 83874 | <1% | 4,150 | $34K | |
| 64635 | <1% | 46 | $34K | |
| 83735 | <1% | 9,145 | $32K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,195 | $31K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,274 | $31K |
| 92587 | <1% | 209 | $30K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,485 | $29K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 119 | $27K |
| 72040 | <1% | 831 | $27K | |
| 94060 | <1% | 263 | $27K | |
| 82550 | <1% | 4,954 | $25K | |
| 81001 | <1% | 13,619 | $25K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,623 | $24K |
| 85730 | <1% | 7,984 | $23K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 500 | $23K |
| 73564 | <1% | 635 | $23K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 137 | $23K |
| 81003 | <1% | 15,653 | $23K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 352 | $22K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 517 | $22K |
| 84702 | <1% | 2,098 | $22K | |
| 87186 | <1% | 4,029 | $21K | |
| 87807 | <1% | 2,015 | $21K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 280 | $19K |
| 87634 | <1% | 330 | $19K | |
| 87077 | <1% | 3,874 | $19K | |
| 97116 | <1% | 1,570 | $19K | |
| 83690 | <1% | 4,540 | $19K | |
| 87040 | <1% | 3,301 | $18K | |
| 86780 | <1% | 1,631 | $18K | |
| 85610 | <1% | 9,250 | $18K | |
| 73090 | <1% | 490 | $18K | |
| 97165 | <1% | 595 | $18K | |
| 83605 | <1% | 3,025 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,548 | $16K |
| 73070 | <1% | 410 | $15K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 19 | $14K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 471 | $14K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,253 | $14K |
| 87088 | <1% | 2,085 | $14K | |
| 73590 | <1% | 371 | $13K | |
| 72050 | <1% | 301 | $13K | |
| 82150 | <1% | 2,791 | $13K | |
| 62323 | <1% | 56 | $12K | |
| 87510 | <1% | 744 | $11K | |
| 87660 | <1% | 744 | $11K | |
| 87480 | <1% | 744 | $11K | |
| 93925 | <1% | 267 | $11K | |
| 86703 | <1% | 885 | $10K | |
| 72070 | <1% | 203 | $10K | |
| 70486 | <1% | 192 | $9K | |
| D2934 | <1% | 13 | $9K | |
| 93923 | <1% | 158 | $9K | |
| 87150 | <1% | 296 | $8K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 319 | $8K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,349 | $8K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 275 | $7K |
| 94726 | <1% | 86 | $7K | |
| 84439 | <1% | 947 | $7K | |
| 87340 | <1% | 819 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 313 | $7K |
| 83655 | <1% | 572 | $7K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 118 | $6K |
| 82803 | <1% | 457 | $6K | |
| 97014 | <1% | 781 | $6K | |
| 71250 | <1% | 134 | $6K | |
| 76770 | <1% | 194 | $6K | |
| 76775 | <1% | 124 | $5K | |
| 93880 | <1% | 140 | $5K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 734 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 12,140 | $5K |
| 86762 | <1% | 433 | $5K | |
| 64490 | <1% | 17 | $5K | |
| 96367 | <1% | 257 | $5K | |
| 95813 | <1% | 42 | $5K | |
| 73552 | <1% | 189 | $5K | |
| 82607 | <1% | 321 | $4K | |
| 84703 | <1% | 683 | $4K | |
| 69210 | <1% | 171 | $4K | |
| 88312 | <1% | 161 | $4K | |
| 82077 | <1% | 408 | $4K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 16 | $4K |
| 87070 | <1% | 647 | $4K | |
| 43235 | <1% | 21 | $4K | |
| 73140 | <1% | 101 | $4K | |
| 85018 | <1% | 1,191 | $4K | |
| 43248 | <1% | 50 | $4K | |
| 88720 | <1% | 758 | $4K | |
| 86696 | <1% | 214 | $3K | |
| 80074 | <1% | 111 | $3K | |
| 85378 | <1% | 758 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,193 | $3K |
| 99490 | Ccm add 20min | <1% | 210 | $3K |
| 85014 | <1% | 2,219 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,469 | $3K |
| 80076 | <1% | 425 | $3K | |
| 86695 | <1% | 214 | $3K | |
| 86140 | <1% | 672 | $2K | |
| 82728 | <1% | 212 | $2K | |
| 84550 | <1% | 652 | $2K | |
| 97533 | <1% | 90 | $2K | |
| 84132 | <1% | 933 | $2K | |
| 86694 | <1% | 167 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 27 | $2K |
| 73523 | <1% | 32 | $2K | |
| 82746 | <1% | 173 | $2K | |
| 85379 | <1% | 415 | $2K | |
| 51798 | <1% | 60 | $2K | |
| 72114 | <1% | 50 | $2K | |
| 87210 | <1% | 483 | $2K | |
| 93296 | <1% | 148 | $2K | |
| 95819 | <1% | 13 | $2K | |
| J3490 | Unclassified drugs | <1% | 10,518 | $1K |
| 82570 | <1% | 344 | $1K | |
| 93922 | <1% | 92 | $1K | |
| 82950 | <1% | 361 | $1K | |
| 82043 | <1% | 239 | $1K | |
| 82330 | <1% | 194 | $1K | |
| 84146 | <1% | 99 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,869 | $1K |
| 87081 | <1% | 227 | $1K | |
| 76536 | <1% | 33 | $1K | |
| 80164 | <1% | 138 | $1K | |
| 80050 | General health panel | <1% | 435 | $1K |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 212 | $1K |
| 82248 | <1% | 329 | $1K | |
| 86706 | <1% | 118 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,737 | $1K |
| 83550 | <1% | 138 | $1K | |
| 85660 | <1% | 237 | $975.81 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,293 | $937.72 |
| 74021 | <1% | 16 | $883.76 | |
| 85651 | <1% | 313 | $869.07 | |
| 73060 | <1% | 23 | $851.05 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $849.41 |
| 82247 | <1% | 270 | $831.01 | |
| 84436 | <1% | 150 | $825.88 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,223 | $816.98 |
| 92567 | <1% | 50 | $798.51 | |
| 95117 | <1% | 28 | $778.94 | |
| 80143 | <1% | 65 | $771.88 | |
| 76830 | Ultrasound, transvaginal | <1% | 14 | $770.12 |
| 92557 | <1% | 15 | $763.49 | |
| 97166 | <1% | 13 | $729.70 | |
| 82947 | <1% | 283 | $676.64 | |
| 93225 | <1% | 16 | $623.52 | |
| 93226 | <1% | 15 | $605.08 | |
| 72131 | <1% | 13 | $584.76 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 288 | $581.42 |
| 77065 | Tomosynthesis, mammo | <1% | 13 | $563.10 |
| 90686 | <1% | 47 | $532.98 | |
| 82565 | <1% | 157 | $517.91 | |
| 73521 | <1% | 20 | $446.95 | |
| 92568 | <1% | 19 | $418.40 | |
| 80185 | <1% | 34 | $399.44 | |
| 80179 | <1% | 31 | $389.97 | |
| 86677 | <1% | 30 | $385.92 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 56 | $360.28 |
| 86038 | <1% | 41 | $328.07 | |
| 80202 | <1% | 42 | $304.75 | |
| 83001 | <1% | 16 | $291.76 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,552 | $249.11 |
| 83540 | <1% | 42 | $241.04 | |
| 84295 | <1% | 173 | $238.97 | |
| 93246 | <1% | 16 | $228.20 | |
| 84153 | <1% | 15 | $226.98 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,184 | $223.47 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 4,001 | $220.57 |
| 85049 | <1% | 88 | $215.96 | |
| 51702 | <1% | 15 | $189.28 | |
| 82272 | <1% | 88 | $177.12 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 2,178 | $166.13 |
| 85046 | <1% | 30 | $149.52 | |
| 84156 | <1% | 56 | $122.15 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,351 | $120.03 |
| 82009 | <1% | 40 | $95.98 | |
| 86431 | <1% | 19 | $88.90 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,392 | $85.67 |
| 96376 | <1% | 3,185 | $76.04 | |
| 82140 | <1% | 12 | $73.15 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,165 | $59.66 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,048 | $58.89 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,935 | $53.90 |
| 84100 | <1% | 58 | $46.97 | |
| 87075 | <1% | 17 | $42.60 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 217 | $38.88 |
| 81000 | <1% | 12 | $33.20 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 996 | $28.67 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 351 | $28.64 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,199 | $19.24 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,048 | $19.11 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 195 | $10.20 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 60 | $6.15 |
| 99152 | <1% | 548 | $5.51 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 694 | $5.49 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 386 | $3.96 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 1,346 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 333 | $0.00 |
| 64494 | 0% | 261 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 743 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 263 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 819 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 1,000 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 624 | $0.00 |
| 94761 | 0% | 1,909 | $0.00 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 837 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 335 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 472 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 874 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 339 | $0.00 |
| C1769 | Guide wire | 0% | 691 | $0.00 |
| 00126 | 0% | 176 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 416 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 228 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 715 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 22 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 376 | $0.00 |
| 36416 | 0% | 220 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 25 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 14 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 14 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 37 | $0.00 |
| 99459 | 0% | 157 | $0.00 | |
| 88341 | 0% | 56 | $0.00 | |
| J3535 | Drug administered through a metered dose inhaler | 0% | 12 | $0.00 |
| 99439 | 0% | 14 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 51 | $0.00 |
| C1729 | Catheter, drainage | 0% | 113 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 186 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 565 | $0.00 |
| 00811 | 0% | 174 | $0.00 | |
| 64636 | 0% | 58 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 450 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 128 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 10,518 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 535 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 42 | $0.00 |
| 00840 | 0% | 156 | $0.00 | |
| 00731 | 0% | 525 | $0.00 | |
| 90715 | 0% | 309 | $0.00 | |
| 64495 | 0% | 235 | $0.00 | |
| 94729 | 0% | 192 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 1,721 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 295 | $0.00 |
| 01992 | 0% | 276 | $0.00 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 27 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 312 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 12 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 142 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 52 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 176 | $0.00 |
| 76942 | 0% | 32 | $0.00 | |
| 64491 | 0% | 17 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 33 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 75 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 40 | $0.00 |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 0% | 12 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 36 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 45 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKENNEDY, DON (REGIONAL CEO)
| Provider | Location | Paid |
|---|---|---|
| Laird Hospital, INC. | Union, MS | $7.23M |
| Laird Hospital, INC. | Meridian, MS | $5.90M |
| Laird Hospital, INC | Meridian, MS | $5.27M |
| Rush Medical Foundation | Quitman, MS | $4.69M |
| Kemper, Cah, INC | Livingston, AL | $4.50M |
| Medical Foundation, INC. | Meridian, MS | $4.20M |
| Kemper Cah, INC. | De Kalb, MS | $4.06M |
| Scott Regional Medical Center, INC. | Morton, MS | $3.77M |
| Kemper Cah, INC | Meridian, MS | $3.39M |
| Rush Hospital/Butler, INC | Butler, AL | $1.94M |
| Medical Foundation, INC. | Meridian, MS | $1.82M |
| The Medical Store, INC. | Meridian, MS | $1.66M |
| Rush Medical Foundation | Meridian, MS | $1.61M |
| Medical Foundation, INC. | Meridian, MS | $1.37M |
| Laird Hospital, INC. | Union, MS | $1.31M |
| Medical Foundation, INC. | Meridian, MS | $1.27M |
| Scott Regional Medical Center, INC. | Morton, MS | $1.21M |
| Rush Medical Foundation | Quitman, MS | $978K |
| Kemper Cah, INC | Meridian, MS | $910K |
| Laird Hospital, INC. | Philadelphia, MS | $898K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.